CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Vitamin D3drug
Likely dose
Vitamin D3 5000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01366885
NCT01366885Phase 2Completed
CompareCT.gov

Study of Vitamin D to Prevent Autism in Newborn Siblings

Oregon Health and Science University·interventional·Posted Jun 6, 2011·Updated Jun 14, 2016

In Brief

A Phase 2 clinical trial evaluating Vitamin D3 for Autistic Disorder. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether by administering vitamin D to mothers who already have at least one child with autism and who are pregnant, that the vitamin D will prevent the recurrence of autism in the newborn sibling.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutistic Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 6, 2011
Enrollment StartFeb 1, 2008
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 15.1 years ago

Interventions

Vitamin D3drug

5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.